Press releases
- Guardant Health Named to TIME100 Most Influential Companies
- Guardant Health to Present Studies at 2024 ASCO Annual Meeting Highlighting Contributions of Its Blood Tests and Real-World Data to Advancing Precision Oncology and Cancer Screening
- FDA Advisory Committee Panel Strongly Recommends Approval of Shield™ Blood Test for Colorectal Cancer Screening as a Primary Non-Invasive Screening Option
- Guardant Health Stock Trading Temporarily Halted; FDA Panel to Assess Premarket Approval Application for Shield Blood Test for Colorectal Cancer Screening
- Guardant Health to Participate in Upcoming Investor Conferences
- Guardant Health Receives EU IVDR Certification for Guardant360® CDx Liquid Biopsy for Tumor Mutation Profiling Across All Solid Cancers and Companion Diagnostic Indications
- Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Guardant Health to present real-world data supporting performance of Shield™ blood test for colorectal cancer screening at 2024 Digestive Disease Week
- Guardant Health Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
- Guardant Health Surpasses 500 Peer-Reviewed Publications Milestone
More ▼
Key statistics
On Thursday, Guardant Health Inc (5GH:FRA) closed at 25.48, 69.64% above the 52 week low of 15.02 set on Apr 22, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 25.16 |
---|---|
High | 26.40 |
Low | 25.16 |
Bid | 24.91 |
Offer | 25.07 |
Previous close | 23.85 |
Average volume | 255.30 |
---|---|
Shares outstanding | 122.37m |
Free float | 116.82m |
P/E (TTM) | -- |
Market cap | 3.32bn USD |
EPS (TTM) | -3.92 USD |
Data delayed at least 15 minutes, as of May 30 2024 07:00 BST.
More ▼